Literature DB >> 10936064

Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications.

M Ferrantini1, F Belardelli.   

Abstract

Cytokine gene transfer is a current approach in studies of gene therapy of cancer IFNs represent valuable cytokines for these studies, since they exert multiple biological effects, including anti-tumor activities. Early studies have been focused on IFN-gamma. Recently, several reports have shown that the transfer of type I IFN (especially IFN-alpha) genes represents a powerful approach for inducing tumor suppression. Recent studies have underscored new IFN-induced activities on immune cells. This knowledge adds a further rationale for the use of IFN-alpha in strategies of gene therapy of cancer and can be exploited for the design of more selective and effective anticancer treatments.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10936064     DOI: 10.1006/scbi.2000.0333

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  5 in total

1.  Type I interferon gene transfer sensitizes melanoma cells to apoptosis via a target activity on mitochondrial function.

Authors:  Paola Matarrese; Luigi Di Biase; Laura Santodonato; Elisabetta Straface; Monica Mecchia; Barbara Ascione; Giorgio Parmiani; Filippo Belardelli; Maria Ferrantini; Walter Malorni
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

Review 2.  Immunomodulatory functions of type I interferons.

Authors:  José M González-Navajas; Jongdae Lee; Michael David; Eyal Raz
Journal:  Nat Rev Immunol       Date:  2012-01-06       Impact factor: 53.106

3.  Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.

Authors:  Masatsugu Obuchi; Marilyn Fernandez; Glen N Barber
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

4.  Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice.

Authors:  S M Santini; C Lapenta; M Logozzi; S Parlato; M Spada; T Di Pucchio; F Belardelli
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

Review 5.  Physiological role of plasmacytoid dendritic cells and their potential use in cancer immunity.

Authors:  Jorge Schettini; Pinku Mukherjee
Journal:  Clin Dev Immunol       Date:  2009-01-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.